The Most Popular Peptides for Longevity & Aesthetics
Learn about the peptides generating the most attention across longevity and aesthetics, why healthcare organizations are watching them, and what current research says about each.
As interest in peptide therapy continues to grow, so does the number of peptides healthcare organizations are expected to understand.
Some have been used in clinical practice for years. Others are emerging from early longevity research. And several are receiving renewed attention following the FDA's ongoing review of compounded peptides.
This article covers the most popular peptides for longevity and aesthetics today that are available for 503A compounding now. For each, we'll explain what it is, why it's being studied, and its regulatory status. Let's dive in.
What Are Longevity Peptides?
In longevity medicine, researchers are studying different peptides for their potential roles in supporting healthy aging and healthspan. Depending on the peptide, research has explored areas including metabolic function, hormone optimization, cognitive health, sleep, recovery, and skin health.
While no peptide has been shown to extend human lifespan, researchers continue investigating how different peptides may influence biological processes associated with healthy aging.
Why Are Peptides Receiving So Much Attention?
According to Google Ads Keyword Planner, searches for "peptide" increased by roughly 398% YoY between June 2025 and July 2026 with over 600K average monthly searches.
Peptides have moved beyond specialized longevity clinics into conversations across primary care, metabolic health, men's and women's health, sleep medicine, and aesthetics.
Patients are becoming more familiar with peptide therapy. Researchers continue publishing new studies. At the same time, several compounded peptides are moving through FDA review, bringing additional visibility to the category.
What Does "Compounded" Mean, and Why Does It Matter Here?
Peptides in FDA Category 1 status are approved to be compounded by licensed 503A pharmacies while under continued review by the FDA.
503A compounding pharmacies create patient-specific medication from 503A bulk drug substances under a valid prescription. The FDA maintains lists of which substances compounding pharmacies can legally use, organized into categories based on available safety data. (For more, see our guide to [FDA peptide reclassification].)
The Most Popular Peptides for Longevity & Aesthetics
No single peptide has been FDA-approved for longevity or aesthetic therapy. Instead, researchers are studying a range of peptides for their potential roles in hormone signaling, cellular metabolism, mitochondrial function, and cognition. The peptides below are currently in FDA category 1 or have recently been recommended for 503A bulk compounding in the July 2026 PCAC meeting.
FDA Category 1 Longevity Peptide
Sermorelin
Sermorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to produce the body's own growth hormone, rather than replacing it directly. It works with the body's existing signaling pathway — an approach many providers and patients find more appealing than direct hormone replacement.
Sermorelin is commonly discussed for hormone optimization, healthy aging, recovery and sleep, body composition, and metabolic health. It has a long history of clinical use in growth hormone stimulation testing and use in pediatric growth studies dating back decades.
Regulatory status: FDA Category 1
PCAC Recommended Peptides: Not Yet Approved for 503A Bulk Compounding
On July 23–24, 2026, FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed several seven peptides for potential inclusion on the Section 503A Bulk Drug Substances List. The committee recommended inclusion of below peptides.
That recommendation is an important milestone, but it is advisory only. It does not by itself place these peptides on the 503A Bulks List, does not make them FDA-approved, and does not yet authorize compounding. FDA must still complete formal notice-and-comment rulemaking, a process that typically takes 12 to 24 months, before these substances could be lawfully compounded under Section 503A.
MOTS-c
MOTS-c is a mitochondrial-derived peptide — one of a small number the body produces directly inside mitochondria, the structures that generate cellular energy. That unusual origin is a big part of its appeal: it's positioned as a more direct lever on cellular aging than peptides that work through hormone signaling.
It's being studied for its potential role in insulin sensitivity, glucose metabolism, exercise physiology, and mitochondrial function. Current published evidence is largely preclinical, drawn from laboratory and animal research, with growing interest in how circulating MOTS-c levels relate to metabolic health and aging in humans.
Regulatory status: Recommended for 503A Bulk Compounding, formal FDA rulemaking still required.
Epitalon
Epitalon is a synthetic tetrapeptide studied for its relationship to cellular aging and telomere biology, the protective structures at the ends of chromosomes that shorten as cells divide. It's become one of the most recognizable names in longevity peptide circles specifically because of that telomere connection, which maps directly onto public interest in cellular aging.
The most recent independently verifiable research is a 2025 study in human cell lines showing dose-dependent telomere extension in laboratory conditions. This is cell-based research, not a clinical trial in patients, and remains the strongest available evidence for how Epitalon may affect telomere biology.
Regulatory status: Recommended for 503A Bulk Compounding, formal FDA rulemaking still required.
Semax
Semax is a peptide with decades of use for cognitive and neurological applications. Its long international track record is a major reason for its popularity among people researching cognitive longevity, even though that history hasn't translated into the kind of trial program required for U.S. approval.
It's studied for cognitive function, neuroprotection, and stress resilience. Published research includes laboratory and animal studies examining its effects on neurotrophic signaling — evidence that remains preclinical rather than based on controlled human trials.
Regulatory status: Recommended for 503A Bulk Compounding, formal FDA rulemaking still required.
KPV
KPV is a small peptide fragment derived from alpha-MSH. Researchers are studying it for anti-inflammatory and immune-modulating effects, especially in gut and inflammatory conditions. Part of its appeal is that it's a very simple, small molecule with a clear, plausible path into inflammation control, which makes it easy to explain even though the evidence behind it is still early.
Regulatory status: Recommended for 503A Bulk Compounding, formal FDA rulemaking still required.
Peptides Waiting to Be Reviewed By PCAC in 2027
The peptides below are currently slated to be discussed in another PCAC meeting scheduled for February 2027. These are not available for 503A compounding at this time.
GHK-Cu
GHK-Cu is one of the most widely discussed peptides in aesthetic medicine — a naturally occurring copper-binding peptide studied for its relationship to collagen production, skin remodeling, wound healing, and hair health. Its popularity comes largely from its long history in topical skincare, where it's one of the more recognizable "active ingredient" peptides outside clinical settings entirely.
Research has explored its role in collagen production, tissue repair, and skin remodeling for decades, primarily through laboratory research and topical studies. Controlled human trial data is more limited for injectable or compounded use than for topical application, where most of the published evidence sits.
Regulatory status: Scheduled for PCAC review in February 2027.
Cathelicidin (LL-37)
LL-37 is an antimicrobial peptide naturally produced by the immune system. Researchers are studying its role in wound healing, immune function, inflammation, and tissue repair, particularly in dermatology and regenerative medicine.
Regulatory status: Scheduled for PCAC review in February 2027.
Dihexa Acetate
Dihexa acetate is an experimental peptide being studied for its effects on neuronal signaling and synaptic connections. Most published research has focused on cognitive and neurological applications, and human clinical evidence remains limited.
Regulatory status: Scheduled for PCAC review in February 2027.
PEG-MGF
Pegylated Mechano Growth Factor (PEG-MGF) is a synthetic version of a naturally occurring growth factor involved in muscle repair following exercise or injury. It is primarily discussed in sports medicine and regenerative medicine, though published human research remains limited.
Regulatory status: Scheduled for PCAC review in February 2027.
Melanotan II
Melanotan II is a synthetic peptide studied for its effects on skin pigmentation. It draws attention for tanning and pigmentation-related use, but it is not FDA-approved, and published human safety data is limited.
Regulatory status: Scheduled for PCAC review in February 2027.
PCAC Recommendation is not FDA Approval for 503A Bulk Compounding
The regulatory landscape for peptide therapy continues to evolve.
It's worth distinguishing PCAC recommendation, from compounding eligibility, from FDA approval. A recommendation is non-binding, and still requires formal rulemaking. If formal rulemaking is published and a peptide is approved for 503A bulk compounding, it is still not FDA-approved, and state pharmacy laws continue to apply on top of the federal framework.
Healthcare organizations should continue monitoring FDA guidance as peptide policy evolves.
Build a Clinically Compliant Peptide Therapy Program In Just Days with OpenLoop
Whether additional peptides move through FDA review or remain under evaluation, healthcare organizations face the same challenge: preparing for growing patient interest while building clinically compliant and safe programs that can adapt as the regulatory landscape changes.
That means thinking beyond any single peptide. Successful programs require extensive clinical operations to provide safe, outcome-driven patient care.
OpenLoop’s already built it. Our virtual care infrastructure, seeing 500,000 patients per month, is built to launch and scale clinically compliant peptide therapy programs—whether you're expanding an existing longevity offering or exploring peptide therapy for the first time. Learn more about how to offer a peptide therapy program at your business.
*This content is intended for general informational purposes only and should not be construed as legal advice. For guidance on your specific situation, please consult a licensed attorney.